Protagonist Earnings Reports

Protagonist Therapeutics reported a net income of $131.7 million for Q4 2024, compared to a net income of $27.3 million for Q4 2023. The company's cash, cash equivalents, and marketable securities totaled $559.2 million as of December 31, 2024. A $165.0 million milestone was earned in Q4 2024 from the icotrokinra license and collaboration agreement.

Protagonist Therapeutics reported its third quarter 2024 financial results, highlighting upcoming milestones for its drug candidates and a strong cash position to support development programs.

Protagonist Therapeutics reported second quarter 2024 financial results, highlighting advancements in rusfertide and JNJ-2113 clinical development, and the expansion of their discovery platform for oral peptides-based programs. The company also noted its addition to the S&P SmallCap 600® index.

Protagonist Therapeutics announced a transformational partnership with Takeda to develop and commercialize rusfertide, allowing reinvestment in peptide therapeutics and expansion of efforts to create a new pipeline. Enrollment is complete in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis. The company expects to nominate an oral IL-17 antagonist development candidate by the end of 2024.

Protagonist Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2023. The company highlighted the worldwide collaboration agreement with Takeda Pharmaceuticals, the progress of JNJ-2113 clinical development program, and the expansion of internal discovery efforts.

Protagonist Therapeutics reported positive Phase 2b data from the FRONTIER 1 study with JNJ-2113 and continued to make progress with rusfertide in the Phase 3 VERIFY study. The company anticipates sharing latest findings at the ASH2023 Annual Meeting.

Protagonist Therapeutics reported positive data from the FRONTIER 1 and REVIVE studies, with JNJ-2113 advancing to Phase 3 and rusfertide's Phase 3 VERIFY study continuing. The company's cash position is strong, with runway through the end of 2025.

Protagonist Therapeutics reported positive topline data from the Phase 2b FRONTIER 1 study of JNJ-2113 and the Phase 2 REVIVE study of rusfertide. They also extended their cash runway through the end of 2025 with a public offering.

Protagonist Therapeutics announced positive results from the Phase 2 FRONTIER 1 study of JNJ-2113 and the REVIVE study of rusfertide. The company is focused on enrolling patients in the Phase 3 VERIFY study of rusfertide and preparing for pre-commercial launch activities. They are also advancing efforts in the oral hepcidin mimetic program.

Protagonist Therapeutics reported its Q3 2022 financial results, highlighting the continued execution of the Phase 3 VERIFY study of rusfertide in polycythemia vera and the appointment of Arturo Molina as Chief Medical Officer.

Protagonist Therapeutics reported their Q2 2022 financial results, highlighting the continued progress of the Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) and a strong cash position with runway through the end of 2024. The company is also advancing other programs, including PN-235 with Janssen and PN-943, while engaging with regulators for guidance on further clinical development.

Protagonist Therapeutics reaffirmed rusfertide as the primary focus, presented topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis, and received a $25 million milestone payment from Janssen.

Protagonist Therapeutics reported its fourth quarter financial results and provided a corporate update, highlighting the advancement of rusfertide into a Phase 3 registrational study, completion of enrollment for PN-943 Phase 2 study, and progression of PN-235 into a Phase 2b study by Janssen.

Protagonist Therapeutics reported progress in its clinical programs, including proof-of-concept data for rusfertide in hereditary hemochromatosis and the resumption of rusfertide clinical studies following the resolution of an FDA clinical hold. PN-235 is advancing into a Phase 2 study in psoriasis in early 2022.

Protagonist Therapeutics reported its financial results for the second quarter ended June 30, 2021. The company highlighted the completion of enrollment for the Phase 2 study of rusfertide in polycythemia vera and the upcoming milestones for rusfertide and PN-943.

Protagonist Therapeutics reported its first quarter 2021 financial results, highlighting the completion of enrollment for the Phase 2 study of rusfertide in polycythemia vera and confirmation of the registrational path forward. The company also noted the progress of PN-943 and anticipated dosing the first subject in the Phase 1 study of PN-232 in the second quarter of 2021.

Protagonist Therapeutics reported its Q4 and full year 2020 financial results, highlighting a year of growth with a focus on expanding the pipeline and advancing development molecules in multiple clinical programs. Key developments include positive interim data from the Phase 2 trial of rusfertide for polycythemia vera and progress with PN-943 for ulcerative colitis. The company also added new assets to the oral IL-23 receptor antagonist program and anticipates a strong cash position to fund operations through mid-2024.

Protagonist Therapeutics reported its financial results for the third quarter ended September 30, 2020. The company's clinical assets PTG-300, PN-943 and PTG-200, are progressing in Phase 2 clinical proof-of-concept studies. Two additional oral interleukin-23 receptor antagonists, PN-235 and PN-232, were selected for advancement into clinical development in collaboration with Janssen.

Protagonist Therapeutics reported its second quarter financial results, highlighting the advancement of three differentiated candidates into Phase 2 development and a successful secondary offering and ATM program, ensuring financial resources to support operations through mid-2023.

Protagonist Therapeutics reported its financial results for the first quarter ended March 31, 2020. The company is focusing on rapidly advancing PTG-300 for polycythemia vera and has reduced operational expenditures, extending the cash runway through mid-2022.

Protagonist Therapeutics reported its financial results for the quarter and year ended December 31, 2019.